|
ABAZA YKANTARJIAN HGARCIA-MANERO G ET AL.: "Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab", BLOOD, vol. 129, no. 10, 2017, pages 1275 - 1283
|
|
ALEXANDER E. PERL GMJORGE E. CORTESANDREAS NEUBAUERELLIN BERMANSTEFANIA PAOLINIPAU MONTESINOSMARIA R. BAERRICHARD A. LARSONCELALET: "Proceedings of the American Association for Cancer Research Annual Meeting 2019", 29 March 2019, AACR, article "Abstract CT184: Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3mut+) related/refractory (R/R) Acute myeloid leukemia (AML): Results from the phase III ADMIRAL trial"
|
|
AU WYFONG BMTAM SKWONG YL: "Feasibility of oral arsenic trioxide treatment for acute promyelocytic leukemia during hemodialysis", ANN HEMATOL., vol. 92, no. 3, 2013, pages 417 - 418
|
|
AUNER HWCENCI S: "Recent advances and future directions in targeting the secretory apparatus in multiple myeloma", BR JHAEMATOL., vol. 168, no. 1, 2015, pages 14 - 25
|
|
CANCER RES, vol. 79, 2019
|
|
CENCI SMEZGHRANI ACASCIO P ET AL.: "Progressive impared protein storage during terminal plasma cells differentiation", EMBOJ., vol. 25, no. 5, 2006, pages 1104 - 1113
|
|
CORTES JEKHALED SMARTINELLI G ET AL.: "Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD Acute myeloid leukaemia (Quantum-R): A multicenter, randomized, controlled, open-label, phase 3 trial", LANCET ONCOL., vol. 20, no. 7, 2019, pages 984 - 997
|
|
FIRKIN FRONCOLATE FHO WK: "Dose adjusted arsenic trioxide for acute promyelocytic leukaemia in chronic renai failure", EUR JHAEMATOL., vol. 95, no. 4, 2015, pages 331 - 335
|
|
GREGORY MAD'ALESSANDRO AALVAREZ-CALDERON F ET AL.: "ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia", PROC NATIACAD SCI USA, vol. 113, no. 43, 2016, pages E6669 - E6678
|
|
ILAND HJCOLLINS MBRADSTOCK K ET AL.: "Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian leukaemia and Lymphoma Group (ALLG) APML4 study: A non-randomized phase 2 trial", LANCET HAEMATOL., vol. 2, no. 9, 2015, pages e357 - 366
|
|
KINDLER TLIPKA DBFISCHER T: "FLT3 as a therapeutic target in AML: Challenging styles after all these years", BLOOD, vol. 116, no. 24, 2010, pages 5089 - 5102
|
|
LARRUE CSALAND EBOUTZEN H ET AL.: "Proteome inhibitors induces FLT3-ITD degradation through autophagy in AML cells", BLOOD, vol. 127, no. 7, 2016, pages 882 - 892
|
|
LO-COCO FDI DONATO LGIMEMA, SCHLENK RF: "German-Austrian Acute Myeloid Leukemia Study G, Study Alliance L. Targeted Therapy alone for acute promyelocytic leukemia", NENGLJMED., vol. 374, no. 12, 2016, pages 1197 - 1198
|
|
LO-COCO FNOTIFIED GVIGNETTI M ET AL.: "Retinoic acid and arsenic trioxide for acute promyelocytic leukemia", NENGLJMED, vol. 369, no. 2, 2013, pages 111 - 121
|
|
MA HSGREENBLATT SMSHIRLEY CM ET AL.: "All-trans retinoic acid symptoms with FLT3 inhibition to eliminated FLT3/ITD+ leukemia stem cells in vitro and in vivo", BLOOD, vol. 127, no. 23, 2016, pages 2867 - 2878
|
|
MASCIARELLI SCAPUANO EOTTONE T ET AL.: "Retinoic acid and arsenic trioxide sensitize acute promyelocytic leukemia cells to ER stress", LEUKEMIA., vol. 32, no. 2, 2018, pages 285 - 294
|
|
MASCIARELLI SCAPUANO EOTTONE T ET AL.: "Retinoic acid symptoms with the unfolded protein response and oxidative stress to induce death celi in FLT3-ITD+ AML", BLOODADV, vol. 3, no. 24, 2019, pages 4155 - 4160
|
|
MCMAHON CMFEMG TCANAANI J ET AL.: "Clonai Selection with RAS pathway Activation median Secondary Clinical resistance to Selective FLT3 inhibitor in Acute Myeloid Leukemia", CANCERDISCOV, vol. 9, no. 8, 2019, pages 1050 - 1063
|
|
MOUJALLEED DMPOMILIO GGHIURAU C ET AL.: "Combining BH3-mimetics to target both BCL-2 and MCL1 has potential activity in pre-clinical models of acute myeloid leukemia", LEUKEMIA, vol. 33, no. 4, 2019, pages 905 - 917
|
|
MUINDI JRFRANKEL SRHUSELTON C ET AL.: "Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia", CANCER RES., vol. 52, no. 8, 1992, pages 2138 - 2142
|
|
OSMAN AEGANDERSON JCHURPEK JE ET AL.: "Treatment of acute promyelocytic leukemia in Adults", J ONCOLPRACT., vol. 14, no. 11, 2018, pages 649 - 657
|
|
PERL AE: "he role of targeted therapy in the management of patients with AML", BLOOD ADV., vol. 1, no. 24, 2017, pages 2281 - 2294
|
|
PERL AEALTMAN JKCORTES J ET AL.: "Selective inhibition of FLT3 by gilteritinib in collapsed or refractory acute myeloid leukaemia: A multicenter, first-in-human, open-label, phase 1-2 study", LANCET ONCOL., vol. 18, no. 8, 2017, pages 1061 - 1075
|
|
SANZ MAMONTESINOS P: "How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia", BLOOD, vol. 123, no. 18, 2014, pages 2777 - 2782
|
|
SCHMIDT-ARRAS DEBOHMER AMARKOVA BCHOUDHARY CSERVES HBOHMER FD: "Tyrosinine phosphorylation regulates maturation of receptor tyrosinine kinases", MOL CELIBIOL., vol. 25, no. 9, 2005, pages 3690 - 3703
|
|
SILVIA MASCIARELLI ET AL: "Retinoic acid synergizes with the unfolded protein response and oxidative stress to induce cell death in FLT3-ITD+ AML", BLOOD ADVANCES, vol. 3, no. 24, 23 December 2019 (2019-12-23), pages 4155 - 4160, XP055754520, ISSN: 2473-9529, DOI: 10.1182/bloodadvances.2019000540
*
|
|
STONE RMMANDREKAR SJSANFORD BL ET AL.: "Midostaurin plus chemotherapy for Acute Myeloid Leukemia with a FLT3 mutation", N ENGL J MEAN., vol. 377, no. 5, 2017, pages 454 - 464
|
|
TSITSIPATIS DJAYAVELU AKMULLER JP ET AL.: "Synergistic killing of FLT31TD-positive AML cells by combined inhibition of tyrosine-kinase activity and N-glycosylation", ONCOTARGET, vol. 8, no. 16, 2017, pages 26613 - 26624
|
|
WANG LNTANG YLZHANG YC ET AL.: "Arsenal trioxide and all-trans-retinoic acid selectively exert synergistic cytotoxicity against FLT3-ITD AML cells via co-inhibition of FLT3 signaling pathways", LEUK LYMPHOMA, vol. 58, no. 10, 2017, pages 2426 - 2438
|